COMPARISON
Angiotensin II vs Vasopressin
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Angiotensin II is authorised or registered in 3 and Vasopressin in 7 of the 10 registers read. Angiotensin II: highest phase Phase 4 (after approval). Vasopressin: highest phase Phase 4 (after approval). 9 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Angiotensin II | Vasopressin | |
|---|---|---|
| Registered trials differs | 364 clinicaltrials.gov · 2026-10-03 | 449 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: ANGIOTENSIN II openfda · 2026-10-03T17:23:44.062Z | FDA-approved: VASOPRESSIN openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Authorised ema · 2026-10-03 | Nothing on record ema read 2026-08-31 |
| EU authorised on differs | 2019-08-23 ema · 2026-10-03 | Not checked no record of "authorisedOn" for vasopressin |
| ATC code differs | C09 ema · 2026-10-03 | Not checked no record of "atcCode" for vasopressin |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Angiotensin II | placebo | Vasopressin | placebo |
|---|---|---|---|---|
| Multi-organ failure | 15.3% | 14.6% | - | - |
| Septic shock | 11.0% | 6.3% | - | - |
| Atrial fibrillation | 10.4% | 10.1% | - | - |
| Thrombocytopenia | 9.2% | 6.3% | - | - |
| Hypokalaemia | 8.0% | 6.3% | - | - |
| Hypotension | 8.0% | 4.4% | - | - |
| Anaemia | 6.7% | 5.7% | - | - |
| Delirium | 5.5% | 0.6% | - | - |
| Hypertension | 5.5% | 5.7% | - | - |
| Pleural effusion | 4.9% | 5.1% | - | - |
Trial register Angiotensin II: 1 placebo-controlled trials; Vasopressin: 3. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Angiotensin II side effects · Vasopressin side effects
LEGAL STATUS
Approval in each country read
| Country | Angiotensin II | Vasopressin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Not on the register | Authorised | Regulator Health Canada |
| Australia | Status unknown | Status unknown | TGA |
| Switzerland | Not on the register | Authorised | Regulator Swissmedic |
| Brazil | Not on the register | Registado | Regulator ANVISA |
| Serbia | Not on the register | Not on the register | Regulator ALIMS |
| Singapore | Not on the register | Registered | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
9 registered trials include both
| NCT05824767 | Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock COMPLETED · updated 2026-07-02 |
|---|---|
| NCT07671365 | Angiotensin II for Post Cardiac Surgery Vasoplegia (ANGII_V) NOT_YET_RECRUITING · updated 2026-06-26 |
| NCT04592744 | Angiotensin 2 for AKI After OLT ACTIVE_NOT_RECRUITING · updated 2026-06-12 |
| NCT07568275 | Comparison of Angiotensin II to Standard Dose Vasopressors on Change in Arterial Elastance ACTIVE_NOT_RECRUITING · updated 2026-05-05 |
| NCT06155812 | Multimodal Vasopressor Strategy in Septic Shock COMPLETED · updated 2026-03-31 |
| NCT06234592 | The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock RECRUITING · updated 2025-04-04 |
| NCT05193370 | Angiotensin II vs. Vasopressin in Septic Shock WITHDRAWN · updated 2024-03-15 |
| NCT04394117 | Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease COMPLETED · updated 2022-03-17 |
| NCT00438412 | Vasoactive Hormones and Oxygen Saturation During Apneic Events in Patients With Obstructive Sleep Apnea SUSPENDED · updated 2008-04-22 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.